Skip to main
LQDA

LQDA Stock Forecast & Price Target

LQDA Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 67%
Buy 22%
Hold 0%
Sell 11%
Strong Sell 0%

Bulls say

Liquidia Corp's recent performance indicates a significant growth trajectory, with an approximate increase in inhaled treprostinil market share from 10% in Q3 to 17%. The strategic decision to expand the sales force by one-third aims to enhance product awareness in a less competitive market, particularly for pulmonary hypertension associated with interstitial lung disease (PH-ILD). Additionally, positive Phase 3 data for the investigational L606 formulation demonstrates a favorable tolerability profile, reinforcing the company’s competitive positioning within the pulmonary hypertension treatment landscape and highlighting its potential for sustained growth.

Bears say

Liquidia Corp is facing significant challenges that contribute to a negative outlook on its stock. The company's primary product, YUTREPIA, has experienced a decline in sales of 11% quarter-over-quarter and is projected to underperform upon its anticipated full approval in 2025 due to limited differentiation from competitor products, cash constraints, and inadequate commercial infrastructure. Additionally, ongoing legal risks surrounding YUTREPIA's exclusivity and potential unfavorable outcomes from patent litigation could severely impact the company's prospects, including the risk of royalty obligations and constraints on the development of its investigational product, L606.

LQDA has been analyzed by 9 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 22% recommend Buy, 0% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Liquidia Technologies Inc (LQDA) Forecast

Analysts have given LQDA a Buy based on their latest research and market trends.

According to 9 analysts, LQDA has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Liquidia Technologies Inc (LQDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.